Postoperative Crizotinib Fails in Early Lung Cancer

(MedPage Today) — Adjuvant crizotinib (Xalkori) failed to improve disease-free survival (DFS) in patients with surgically resected early-stage ALK-positive non-small cell lung cancer (NSCLC), the phase III ECOG-ACRIN E4512 trial showed.
Among…